Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched-Pair Analysis of 100 Patients
- 1 July 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Surgeons
- Vol. 221 (1), 123-128
- https://doi.org/10.1016/j.jamcollsurg.2015.02.025
Abstract
The efficacy and safety of magnetic sphincter augmentation (MSA) with the LINX device (Torax Medical) has been reported in several short-and long-term studies, rivaling historic results of laparoscopic Nissen fundoplication (LNF), but with fewer side effects. However, there have been no studies comparing patients with similar disease to validate these results. We conducted a retrospective analysis of 1-year outcomes of patients undergoing MSA and LNF from June 2010 to June 2013. Patients were matched using propensity scores incorporating multiple preoperative variables. Outcomes were measured by GERD Health Related Quality of Life scores, proton-pump inhibitor use, satisfaction, and complications. One hundred and seventy-nine patients met inclusion criteria, 62 MSA and 117 LNF. Propensity score matching identified 50 patients in both groups using the "best-fit" model with a caliper of 0.5 SD. At 1 year after surgery, both groups had similar GERD Health Related Quality of Life scores (4.2 MSA and 4.3 LNF; p = 0.897) and proton-pump inhibitor use (17% of MSA and 8.5% of LNF; p = 0.355). Although there was no difference in the number of patients reporting mild gas and bloating (27.6% MSA and 27.6% LNF; p = 1.000), there were no patients with severe gas and bloating in the MSA group compared with 10.6% in the LNF group (p = 0.022). More LNF patients were unable to belch (8.5% of MSA and 25.5% of LNF; p = 0.028) or vomit (4.3% of MSA and 21.3% of LNF; p = 0.004). The incidence of postoperative dysphagia was similar between the groups (46.8% MSA and 44.7% LNF; p = 0.766). Analogous GERD patients had similar control of reflux symptoms after both MSA and LNF. The inabilities to belch and vomit were significantly fewer with MSA, along with a significantly lower incidence of severe gas-bloat symptoms. These results support the use of MSA as first-line therapy in patients with mild to moderate GERD.Keywords
This publication has 10 references indexed in Scilit:
- Short-Term Outcomes Using Magnetic Sphincter Augmentation Versus Nissen Fundoplication for Medically Resistant Gastroesophageal Reflux DiseaseThe Annals of Thoracic Surgery, 2014
- Esophageal Sphincter Device for Gastroesophageal Reflux DiseaseThe New England Journal of Medicine, 2013
- The LINX® reflux management system: confirmed safety and efficacy now at 4 yearsSurgical Endoscopy, 2012
- Regurgitation Is Less Responsive to Acid Suppression Than Heartburn in Patients With Gastroesophageal Reflux DiseaseClinical Gastroenterology and Hepatology, 2012
- Evolution of gastro‐oesophageal reflux disease over 5 years under routine medical care – the ProGERD studyAlimentary Pharmacology & Therapeutics, 2011
- Laparoscopic Sphincter Augmentation Device Eliminates Reflux Symptoms and Normalizes Esophageal Acid ExposureAnnals of Surgery, 2010
- Gastroesophageal Reflux DiseaseThe New England Journal of Medicine, 2008
- The development of the GERD-HRQL symptom severity instrumentDiseases of the Esophagus, 2007
- The rise and fall of antireflux surgery in the United StatesSurgical Endoscopy, 2006
- Clinical Trials Evaluating Endoscopic GERD Treatments Is It Time for a Moratorium on the Clinical Use of These Procedures?The American Journal of Gastroenterology, 2006